BNP Paribas Financial Markets
XENE icon

BNP Paribas Financial Markets’s Xenon Pharmaceuticals XENE Stock Holding History

BNP Paribas Financial Markets’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.92M Sell
31,791
-48,601
-60% -$2.7M ﹤0.01% 2821
2026
Q1 		$4.67M Sell
80,392
-13,070
-14% -$602K ﹤0.01% 2078
2025
Q4 		$4.19M Sell
93,462
-65,776
-41% -$2.76M ﹤0.01% 2160
2025
Q3 		$6.39M Buy
159,238
+141,394
+792% +$4.98M ﹤0.01% 1829
2025
Q2 		$559K Buy
17,844
+14,634
+456% +$477K ﹤0.01% 3261
2025
Q1 		$108K Sell
3,210
-122
-4% -$4.63K ﹤0.01% 4012
2024
Q4 		$131K Sell
3,332
-140
-4% -$5.79K ﹤0.01% 4066
2024
Q3 		$137K Sell
3,472
-8,144
-70% -$328K ﹤0.01% 3385
2024
Q2 		$453K Buy
11,616
+3,295
+40% +$132K ﹤0.01% 2720
2024
Q1 		$358K Buy
8,321
+3,931
+90% +$181K ﹤0.01% 3023
2023
Q4 		$202K Buy
4,390
+2,707
+161% +$95.6K ﹤0.01% 3210
2023
Q3 		$57.5K Buy
1,683
+242
+17% +$9.05K ﹤0.01% 3440
2023
Q2 		$55.5K Buy
1,441
+413
+40% +$16.4K ﹤0.01% 3439
2023
Q1 		$36.8K Sell
1,028
-498
-33% -$18.4K ﹤0.01% 3468
2022
Q4 		$60.2K Sell
1,526
-3,430
-69% -$125K ﹤0.01% 3384
2022
Q3 		$179K Buy
4,956
+2,212
+81% +$79.5K ﹤0.01% 3543
2022
Q2 		$83.5K Buy
2,744
+1,410
+106% +$42.6K ﹤0.01% 3410
2022
Q1 		$40.8K Buy
1,334
+1,254
+1,568% +$37.5K ﹤0.01% 3594
2021
Q4 		$2.5K Sell
80
-422
-84% -$12.6K ﹤0.01% 3978
2021
Q3 		$7.67K Buy
502
+12
+2% +$209 ﹤0.01% 3686
2021
Q2 		$9.12K Buy
490
+261
+114% +$4.81K ﹤0.01% 3749
2021
Q1 		$4.1K Buy
+229
New +$3.88K ﹤0.01% 3875
2020
Q4 		– Sell
-95
Closed -$1.05K – 4231
2020
Q3 		$1.05K Buy
+95
New +$1.12K ﹤0.01% 4084

Other funds holding XENE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BNP Paribas Financial Markets's XENE Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Xenon Pharmaceuticals (XENE) stake by 60% in Q2 2026, selling an estimated $2.7M and leaving 31,791 shares worth $1.92M. The position accounts for ﹤0.01% of the portfolio, ranked #2821.

BNP Paribas Financial Markets first reported a position in XENE in Q3 2020 and has held it in 23 quarters since. The position peaked at $6.39M in Q3 2025. 286 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • BNP Paribas Financial Markets held 31,791 shares of Xenon Pharmaceuticals worth $1.92M as of Q2 2026.
  • BNP Paribas Financial Markets sold 48,601 Xenon Pharmaceuticals shares in Q2 2026, an estimated $2.7M.
  • Xenon Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #2821 holding.
  • BNP Paribas Financial Markets first reported a position in Xenon Pharmaceuticals in Q3 2020 and has held it in 23 quarters since.
  • BNP Paribas Financial Markets's Xenon Pharmaceuticals position peaked at $6.39M in Q3 2025.
  • 286 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.